

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Kristof Van Emelen et al.

Serial No. : Art Unit:

Filed : Examiner:

For : AMINOALKYL SUBSTITUTED (BENZODIOXAN, BENZOFURAN OR
BENZOPYRAN) DERIVATIVES

Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

☒ In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified national application (other than a continued prosecution application under §1.53(d)),

within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of a request for continued examination under §1.114, no additional fee is required.

☐ In accordance with §1.129(a), this Information Disclosure Statement is being filed in connection with ☐ the first or ☐ second After Final Submission, therefore:

- ☐ Statement in Accordance with §1.97(e) (attached);
or
- ☐ Please charge Deposit Account No. 10-0750/JAB-1487/ECC the fee of \$180.00 as set forth in §1.17(p).

☐ In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, or an action that otherwise closes prosecution and that it is accompanied by one of:

- ☐ Statement in Accordance with §1.97(e) (attached);
or
- ☐ Please charge Deposit Account No. 10-0750/JAB-1487/ECC the fee of \$180.00 as set forth in §1.17(p).

☐ In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance

under §1.311 but before the payment of the Issue Fee.
Applicant(s) hereby petition(s) for consideration of this
Information Disclosure Statement. Included are: Statement in
Accordance with §1.97(e) as set forth below and the fee of
\$180.00 as set forth in §1.17(p).

☒ Copies of each of the references listed on the
attached Form PTO-1449 are enclosed herewith.

☐ Copies of references listed on the attached Form PTO-
1449 are enclosed herewith EXCEPT THAT:

☐ In view of the voluminous nature of references
[list as appropriate], and the likelihood that
these references are available to the Examiner,
copies are not enclosed herewith.

☐ If any of the foregoing publications are not
available to the Examiner, Applicant will
endeavor to supply copies at the Examiner's
request.

☒ There are no listed references which are not in the
English language, or for which no English language abstract or
corresponding U.S. patent is enclosed.

☐ The relevance of those listed references which are not
in the English language is as follows:

☐ Attached are copies of search report(s) from
corresponding patent application(s), which are listed on the
attached Submission Under MPEP 609 D.

☒ Attached are the following non-published pending patent applications which may be deemed relevant, which are listed on the attached Submission Under MPEP 609 D.

Attorney Docket No. JAB-1488, filed concurrently herewith, entitled "Pyrrolidiny, Piperidinyl or Homopiperdinyll substituted (Benzodioxan, Benzofuran or Benzopyran} Derivatives"

Please charge any deficiency or credit any overpayment to Deposit Account No. 10-0750/JAB-1487/ECC. This form is submitted in triplicate.

Respectfully submitted,



Ellen Ciambrone Coletti
Reg. No. 34140
Attorney for Applicants

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003
(732) 524-2359
DATED: November 30, 2001